Fig. 1From: The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical studyStudy flow chart. Collectively, 40 patients were enrolled and 32 patients completed a 6-month follow-up; 4 discontinued the drug due to inefficacy and 4 due to adverse eventsBack to article page